Uncategorized

Novartis’ radioligand therapy Lutathera could soon face generic competition

Novartis’ radioligand therapy Lutathera could soon face generic competition

Published

2 weeks ago

on

The radioligand field is on the cusp of a major competitive moment, as a rival looks to bring the first generic to a market that’s been dominated by Novartis.

Radioligand therapy aims to bring the …​ ​Read More

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version